NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 88.95M -5.6% |
| Revenue (ttm) | n/a -51.8% |
| Net Income | -38.64M |
| EPS | -1.87 |
| Shares Out | 25.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,991 |
| Open | 3.600 |
| Previous Close | 3.630 |
| Day's Range | 3.300 - 3.600 |
| 52-Week Range | 3.005 - 12.990 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 16.00 (+366.47%) |
| Earnings Date | Aug 18, 2026 |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra... [Read more]
Financial Performance
In 2025, NTHI's revenue was $39,990, a decrease of -51.82% compared to the previous year's $83,000. Losses were -$62.15 million, 422.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NTHI stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 366.47% from the latest price.
News
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of t...
Wall Street is Watching These Biotechs
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one of the most significant periods in its corporate history after securing it...
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where ...
NeOnc Technologies Holdings Proxy statement: Proxy filing
NeOnc Technologies Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
NeOnc Technologies Holdings Proxy statement: Proxy filing
NeOnc Technologies Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
International Regulatory Validation Has Preceded Several Recent FDA Success Stories, Though Significant Development Risks Remain Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies H...
NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212
DALLAS, June 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator, as it advances a growing pipeline of therapies...
Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND
DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) – NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer, as it advances multiple...
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 6...
NeOnc Technologies files to sell 555,554 shares of common stock for holders
16:25 EDT NeOnc Technologies (NTHI) files to sell 555,554 shares of common stock for holders
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
New Funding Structure Includes Redemption Rights, Ownership Limitations, and Conversion Floor as Investors Monitor Upcoming Clinical Updates Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Te...
NeOnc Technologies Holdings Registration statement: Registration filing
NeOnc Technologies Holdings filed a registration statement on June 15, 2026, providing details about a securities offering with the SEC.
NeOnc Technologies Holdings Proxy statement: Proxy filing
NeOnc Technologies Holdings filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
NeOnc Technologies Advances Novel Neuro-Oncology Therapies Targeting Glioblastoma and Other Hard-to-Treat Brain Cancers Houston, Texas--(Newsfile Corp. - June 9, 2026) - For years, artificial intellig...
The Next Great AI Revolution May Be Drug Delivery
NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) can...
NeOnc Technologies initiated with a Buy at Alliance Global
Alliance Global initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $13 price target The company is focused on developing intranasally-delivered small molecules for brain tumors, nam...
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase 2 progra...
NeOnc Technologies initiated with a Buy at Maxim
Maxim initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $20 price target
NeOnc Technologies Holdings Earnings release: Q1 2026
NeOnc Technologies Holdings released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
NeOnc Technologies Holdings Quarterly report: Q1 2026
NeOnc Technologies Holdings has published its Q1 2026 quarterly earnings report on May 18, 2026.
Biotech's Next Wave May Already be in Motion
DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, la...
Where Executives Are Doubling Down on Their Companies' Fortunes
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money ...
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovat...